Regenxbio is pushing its Duchenne muscular dystrophy gene therapy into pivotal development, with a BLA planned for ...
Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop ...
Incyte’s pipeline updates on Monday bring into question the value of its $750 million Escient acquisition in April 2024—and ...
Phase II results for Cybin’s psilocin therapy showed remission rates of 71%, but just eight patients made it to the 12-month ...
Wegovy is being made available to Chinese patients five months after its approval in the country. Novo will sell the medicine ...